Possible Interaction: Glucose and Atorvastatin

“CONCLUSION Сonclusions: Despite of the beneficial reductions in LDL and total cholesterol, at rvastatin tr eatment on a dose 40 mg resulted in significant increase of fas ting glucose, i nsulin levels and insulin resistance pertaining to those patients.”

“2] ICAM-1: Increased ICAM1 in high glucose condition was reduced by atorvastatin.”

“In vitro monocyte adhesion assay revealed that atorvastatin reduced monocyte adhesion on endothelial cells in high glucose condition , which was reversed by Skp2 knock-down.”

“In subgroup analysis of individual statins, use of atorvastatin , rosuvastatin, pitavastatin and simvastatin had significant association with increase in fasting glucose.”

“HRPE cells treated with glucose or EDPs with the addition of atorvastatin had a statistically significant decrease of TIMP-2 expression; glucose alone decreased MMP-1 expression.”

“Compared with placebo, atorvastatin resulted in a significant (p = 0.05) reduction in the HOMA index (-21%), fasting C-peptides (-18%), glucose (area under the curve during the oral glucose tolerance test, -7%), and a borderline (p = 0.08) reduction of insulin (-18%).”

“In HFD mice, atorvastatin not pravastatin significantly increased blood glucose levels following glucose or insulin dose and decreased expression of membrane not total GLUT4 protein in muscle.”

“The intravenous glucose tolerance test showed that atorvastatin-treated rabbits had an increased area under the curve for time-dependent glucose levels after a bolus injection of glucose , which was completely reversed by metformin treatment.”

“ Atorvastatin blocked these toxic effects of high glucose, being more effective against 50 mmol/L glucose (protective effects were observed above 0.5 μmol/L) than against 83 mmol/L (protective effects were observed above 2.5 μmol/L).”

“Patients taking atorvastatin 40 mg/day (group 2) following MI showed increases in levels of glucose , insulin, and C-peptide and insulin resistance progression after 12 months of therapy, as evidenced by increased quantitative insulin sensitivity check index scores and detection of new T2DM cases.”